Skip to main content
Cytogen, Inc. logo

Cytogen, Inc. — Investor Relations & Filings

Ticker · 217330 ISIN · KR7217330000 KO Manufacturing
Open in API
Filings indexed 436 across all filing types
Latest filing 2026-02-27 Major Shareholding Noti…
Country KR South Korea
Listing KO 217330

About Cytogen, Inc.

https://www.cytogenlab.com/

Cytogen, Inc. is a biotechnology company specializing in liquid biopsy platforms for precision oncology. The company has developed proprietary technology for the rapid isolation and analysis of viable Circulating Tumor Cells (CTCs) from whole blood. Its core offering, the SmartBiopsy Platform, utilizes a high-density microporous chip with microfluidics and nanotechnology to capture CTCs efficiently. This non-invasive diagnostic approach is designed to support early cancer detection, treatment monitoring, and the advancement of personalized medicine for cancer patients.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is the standard Korean regulatory filing for reporting significant changes in share ownership (often referred to as the 5% rule filing). It details the reporting entity, the issuer (CytoGen), the number of shares held, the purpose of holding (management influence), and specific transaction details. This falls under the 'Major Shareholding Notification' category.
2026-02-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. It details the change in share ownership by an executive (Jeon Byung Hee) of Cytogen. This type of filing is specifically categorized as 'Director's Dealing' (DIRS) as it reports personal share transactions by company directors and executives.
2026-02-27 Korean
[기재정정]임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 98% confidence The document is a 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주특정증권등거래계획보고서) filed by Cytogen. It details a correction to a previously submitted trading plan, specifically changing the transaction method from 'off-exchange' to 'after-hours trading'. This type of filing is a regulatory requirement for insiders to disclose their future trading intentions to the financial authorities (Financial Supervisory Service/Korea Exchange). Since it does not fit into standard categories like 'Director's Dealing' (which is for completed trades) or 'Share Issue', it falls under the 'Regulatory Filings' category as a miscellaneous but mandatory disclosure.
2026-02-23 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's representative director (CEO). It details the previous and new directors, the reason for the change (dismissal of a co-CEO), the date of the board resolution, and the professional background of the new CEO. This falls directly under the category of Board/Management Information.
2026-02-20 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from a Korean company (Cytogen) announcing a significant change (over 30%) in revenue or profit structure. This is a standard financial disclosure required by the Korea Exchange (KRX) when financial results deviate significantly from the previous period. Since it provides the initial announcement of financial performance highlights (revenue, operating profit, net income) before the final audited annual report is finalized, it falls under the 'Earnings Release' category. FY 2025
2026-02-13 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 98% confidence The document is a 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주특정증권등거래계획보고서) filed with the Financial Supervisory Service (FSS) and the Korea Exchange. This is a regulatory filing required by South Korean law for insiders planning to trade company shares. Since it involves an executive (the CEO) reporting a future trading plan, it falls under the category of Director's Dealing (DIRS), which covers insider transactions and related reporting requirements.
2026-01-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.